JAAD Weighs Photodynamic Therapy for Onychomycosis Evidence

The Journal of the American Academy of Dermatology published an evidence review on photodynamic therapy (PDT, a light-activated treatment using a photosensitizing agent) for onychomycosis in its November 2026 issue, Volume 95, Issue 5. Authors Nuran C. Golbasi and Shari R. Lipner set out to interpret what the current literature does — and does not — support.

Onychomycosis, a fungal infection of the nail unit, remains one of the most stubbornly recurrent conditions in general dermatology practice. Topical agents struggle to penetrate the nail plate, and oral antifungals carry hepatic monitoring requirements and drug-interaction burdens. That gap explains why light-based alternatives keep attracting investigator attention.

Why examine PDT now?

PDT works by applying a photosensitizer to infected tissue and then activating it with light of a matching wavelength, generating reactive oxygen species that destroy fungal elements. The technique already holds regulatory grounding in actinic keratosis treatment, which is precisely why claims about its nail applications warrant scrutiny rather than enthusiasm.

Golbasi and Lipner frame their review as an interpretation of the existing evidence rather than a promotional survey. The distinction matters. Interpretive reviews in JAAD typically grade study quality, flag heterogeneity in protocols, and separate case-series signals from controlled-trial findings. Readers should expect exactly that discipline here.

What the review format signals

The authors chose a synthesis format rather than a new trial report. That choice indicates the field has accumulated enough studies to warrant appraisal, but not enough consistency — in photosensitizer choice, incubation time, light parameters, or cure definitions — to support a meta-analytic verdict.

For clinicians, the practical questions are concrete: which photosensitizers were studied, what light sources and doses were used, what mycological and clinical cure rates were reported, and how those outcomes compare against approved topical and oral therapies. A review that answers those questions with graded evidence does more service than any single-arm series.

What remains unproven

Every promise in this field carries a caveat. The source announcement does not specify effect sizes, comparator arms, or the number of studies included, and no figures should be assumed before the full text is read. What the citation establishes is the publication event itself: a peer-reviewed appraisal in the field's leading journal, dated November 2026, authored by a group with established expertise in nail disease — Lipner's group at Weill Cornell has published extensively on onychomycosis diagnostics and therapeutics.

Regulatory status also remains open. PDT for onychomycosis has no dedicated approval in most jurisdictions, so any clinical use would rest on off-label, evidence-based judgment. Reimbursement pathways are correspondingly uncertain, a practical constraint for practices weighing device investment against an unapproved indication.

The access question

If the review finds PDT evidence supportive, cost and access will shape adoption more than efficacy alone. A course of PDT requires in-office equipment, photosensitizer application, and incubation time — a resource profile closer to in-office procedures than to dispensing a prescription. Where oral antifungals fail or are contraindicated, however, that procedural burden may be acceptable.

If the review finds the evidence insufficient, the field will need standardized protocols before PDT can move beyond case-series territory. Either outcome advances practice: a clear negative or a qualified positive both discipline a literature that has drifted on enthusiasm.

Dermatologists managing recalcitrant nail disease should read the full text when it posts, with attention to how the authors grade each study and whether they define a threshold for adopting PDT in refractory cases.